Quality of life matters! Join Poster author @amybeumer of the Patient-Centered Dosing Initiative (PCDI @TheRightDose) at poster walkthroughs next week to discuss findings from a large MBC patient survey that highlight the need for more individualized dosing strategies.

As we kick off #SABCS25, excited to share our new recommendations paper for capivasertib in HR MBC: 10 practical recommendations to optimize treatment and patient experience. nature.com/articles/s41523-0… @HeatherMoore16 @ErikaHamilton9 @jhaveri_komal @hoperugo @WinshipAtEmory

Attending #SABCS25? Join the @GRASPtweets reception, one of the few opportunities for scientists, clinicians & patient advocates to connect. It's where so many collaborations are born to bring the patient experience to research! Register here: graspcancer.org/event/sabcs2…

What are the most important takeaways from #ESMO25 for #BreastCancer care? Join @DanaFarber experts on Nov 14th for our live #BreastCancerBreakthroughs webinar discussing the latest clinical advances, research highlights, and their impact on patient care. 📅November 14, 1:30–2:30 PM EST 👉Register for free today: bit.ly/3WvQUhi Moderator: @DrHBurstein Panelists: @stolaney1 @nlinmd @FilipaLynce #AnaGarridoCastro

I gave a talk this weekend at Curio Expert Meeting in Tampa, FL with the task of educating the community on updates in ER , HER2- MBC. It is getting to be quite the challenge! Here are my thoughts on likely algorithms in 2026. The bar is getting higher on safety and efficacy.

As October ends and pink ribbons fade, we cannot forget Stage IV—not for a single day. Only 13% of breast cancer research funding goes to the disease that kills. Thank you for following our #METober posts. Please keep sharing and spreading the word #UntilNoOneDiesFromMBC

Ask any breast oncologist today, and they’ll tell you they prefer anthracycline-free regimens in HER2-positive breast cancer — and that anthracyclines don’t improve response rates. So how did we accept a control arm containing anthracyclines in the DESTINY-Breast11 trial, which began in October 2021? We can’t simply call this a sponsor-driven choice. It’s the physicians who persuade patients to enroll — physicians who also receive payment for every screening and treatment visit. Let’s be honest: how do you justify to your patients a control arm that doesn’t reflect your own real-world practice? I’m open to any kind of criticism; just don’t come to me with the fairytale that anthracycline-containing arms are still the “standard.” I know this sounds a bit harsh, but we’re exhausted from having to point out flaws in control arms every time new trial results are presented. We’re now seeing control arms that no longer represent today’s standards — some even belong to history (eg. ARANOTE trial). It’s a call to all of us, as physicians, to think more carefully about the trials we support — if our genuine goal is the health and well-being of every patient, including those in the control arm.

About two-thirds of MBC patients have liver metastases at death, and 1 in 4 already have liver involvement at diagnosis. Liver transplants aren’t an option for MBC patients—another reason why we need more research for better treatments. #UntilNoOneDeisFromMBC #Research

RCT on timing of pegfilgrastrim after CT shows significantly reduced bone pain with 72-hour timing as compared to 24- and 48-hour timing #ESMO25 @myESMO @OncoAlert

Grateful for the chance to chair the #ESMO25 ADC educational session & present on ADC toxicities. With ADCs moving to the curable setting across cancers, it’s critical to be aware of how to mitigate their side effects. For an in-depth dive into the topic: nature.com/articles/s41571-0…

SONIA overall survival analysis = no significant difference 1L vs 2L CDK4/6i, except premenopausal; draws same criticisms RE: low OS compared to historical trial, non-standard of care single agents & CDK4/6. Still impressive data adding value. #ESMO25 @OncoAlert